Navigation Links
Idenix Pharmaceuticals Reports Second Quarter and Six Month 2009 Financial Results
Date:7/20/2009

CAMBRIDGE, Mass., July 20 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today reported unaudited financial results for the second quarter and six months ended June 30, 2009. At June 30, 2009, Idenix's cash, cash equivalents and marketable securities totaled $51.7 million.

Business Highlights

  • Idenix announced today that it had successfully completed a proof-of-concept study of its lead HCV antiviral development program, IDX184, a novel once-daily liver-targeted nucleotide prodrug. This double-blind, placebo-controlled, monotherapy, dose-escalation study in HCV genotype-1-infected patients evaluated the safety and antiviral activity of IDX184. For more information on the results of this study, please see the related press release issued today by Idenix.
  • The company continued to advance its two preclinical HCV antiviral programs. Idenix is finalizing IND- or CTA-enabling preclinical studies for IDX375, a non-nucleoside polymerase inhibitor, and is preparing documentation to support initial regulatory filings. The company has synthesized the first kilogram of its lead protease inhibitor drug candidate and has initiated 28-day chronic toxicology studies in two species to support regulatory applications.
  • Finally, during the quarter, Idenix streamlined operations with the closure of its screening facility in Cagliari, Italy. This activity is now being performed at the company's laboratory in Cambridge, Massachusetts. As a result, Idenix reduced its workforce by 18 employees and incurred a restructuring charge in the quarter of $1.5 million.

"Our focus this year has been on the advancement of our HCV discov
'/>"/>

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Idenix to Host Conference Call Discussing Second Quarter 2009 Financial Results
2. Idenix Pharmaceuticals to Present at The Deutsche Bank 2009 Health Care Conference
3. Idenix Pharmaceuticals Reports First Quarter Financial Results
4. Idenix Pharmaceuticals Reports Data From Three Hepatitis C Development Programs at the 44th Annual Meeting of the European Association for the Study of the Liver
5. Idenix Pharmaceuticals to Present at the Canaccord Adams Hepatitis C Conference
6. Idenix Announces Data Presentations from Three HCV Discovery and Development Programs at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL)
7. Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results
8. Idenix to Host Conference Call Discussing Fourth Quarter 2008 Financial Results
9. Idenix Pharmaceuticals to Present at the JP Morgan 27th Annual Healthcare Conference
10. Idenix Pharmaceuticals to Present at Deutsche Banks 2008 Biotech Boston Confab
11. Idenix Pharmaceuticals Reports Third Quarter and Nine Month Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... , May 27, 2015  Tikcro Technologies Ltd. ... ended March 31, 2015. Aviv ... we continued pre-clinical work to generate functional specific antibodies, ... early stage, we are encouraged by the development progress. ... as new antibodies which modulate immune checkpoints gain clinical ...
(Date:5/27/2015)... Calif. , May 27, 2015  CytomX, ... treatment of cancer, today announced the appointments of ... and Cynthia Ladd as senior vice ... Goeltz was chief financial officer of Onyx Pharmaceuticals, ... an independent consultant and legal counsel to several ...
(Date:5/27/2015)... OAKS, Calif. , May 27, 2015  Ceres, ... has been awarded a U.S. patent for a genetic ... in areas such as research, product development and plant ... in regulating key biosynthetic processes that are the target ... offer other seed companies a commercial license to the ...
(Date:5/27/2015)... 2015 The Medical Innovation Impact Index ... regulation on medical innovation, has been developed at the ... Fairleigh Dickinson University’s ( FDU ) Rothman Institute of ... pertains to new FDA (Food & Drug Administration) draft ... approval of certain medical devices. , “The main ...
Breaking Biology Technology:Tikcro Technologies Reports First Quarter 2015 Results 2Tikcro Technologies Reports First Quarter 2015 Results 3CytomX Expands Executive Leadership Team 2CytomX Expands Executive Leadership Team 3Ceres Awarded Patent for Innovation in Soybean 2Ceres Awarded Patent for Innovation in Soybean 3Medical Innovation Impact Index Launched at Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) under the Rothman Institute 2
... 2011 Jennerex, Inc., a private clinical-stage biotherapeutics company ... oncolytic virus products for cancer, today announced the publication ... the journal Nature . For the first time ... infect, replicate and express transgene products within ...
... in the journal Nature Communications , a ... which includes Nobel Prize winning scientists Professor Andre ... crucial recipe for improving characteristics of graphene devices ... communications. By combining graphene with metallic nanostructures, ...
... Aug. 30, 2011 Farmers in North Carolina will ... a partnership by Perdue AgriBusiness and Winston-Salem-based Technology Crops ... the crop looks identical to canola, but the oil ... applications, especially industrial uses.  Grown in trials in North ...
Cached Biology Technology:Jennerex Publishes Clinical Data in Journal, Nature, Demonstrating Intravenous Delivery of Multi-Mechanistic Cancer-Targeted Oncolytic Poxvirus JX-594 to Tumors 2Jennerex Publishes Clinical Data in Journal, Nature, Demonstrating Intravenous Delivery of Multi-Mechanistic Cancer-Targeted Oncolytic Poxvirus JX-594 to Tumors 3Jennerex Publishes Clinical Data in Journal, Nature, Demonstrating Intravenous Delivery of Multi-Mechanistic Cancer-Targeted Oncolytic Poxvirus JX-594 to Tumors 4Jennerex Publishes Clinical Data in Journal, Nature, Demonstrating Intravenous Delivery of Multi-Mechanistic Cancer-Targeted Oncolytic Poxvirus JX-594 to Tumors 5Graphene's shining light could lead to super-fast Internet 2Perdue AgriBusiness and TCI Collaborate to Bring Profitable New Crop to North Carolina 2Perdue AgriBusiness and TCI Collaborate to Bring Profitable New Crop to North Carolina 3Perdue AgriBusiness and TCI Collaborate to Bring Profitable New Crop to North Carolina 4
(Date:5/8/2015)... -- Synaptics Inc. (NASDAQ: SYNA ), the leading developer ... executive management team will present at the following investor events: ... Conference Date: May 18, 2015 Time: 10:40am ET ... Cowen and Company Technology, Media & Telecom ... New York Palace Hotel, New York, NY ...
(Date:5/5/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... commerce market, reminds investors and media that  Mr. David ... CARTES SECURE CONNEXIONS AMERICA 2015, held in Washington ... three-day conference is organized into a series of nine session ... Global Fraud: Where is the Trust in Cyberspace? and ...
(Date:4/27/2015)... , Apr. 27, 2015 Profile Solutions, Inc. ... and security systems is pleased to announce that Dr ... a consultant and member of its scientific advisory board. ... known as a thought leader in technology-enhanced learning models. ... Group, and has published studies and books focused on ...
Breaking Biology News(10 mins):Synaptics to Present at Upcoming Investor Conferences 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4
... CORVALLIS, Ore. After being hunted to local extinction ... ancestral calving grounds, the southern right whales of mainland New ... has shown for the first time that whales from a ... way back to the New Zealand mainland. Before the ...
... examine so-called epigenetic influences on the DNA makeup of ... suggest cancer treatment might eventually be more tolerable and ... get back to normal in addition to strategies for ... in Nature Genetics , the investigators focused on ...
... They can be found everywhereorganized communities of bacteria sticking ... biofilms are responsible for some of the most virulent, ... these communities develop is lacking. A recent ... light on the process. The scientists discovered that a ...
Cached Biology News:Fighting back from extinction, New Zealand right whale is returning home 2Fighting back from extinction, New Zealand right whale is returning home 3Johns Hopkins scientists expose cancer cells' universal 'dark matter' 2Johns Hopkins scientists expose cancer cells' universal 'dark matter' 3Syracuse University biologist discovers key regulators for biofilm development 2
... is an optical unit that can be ... Dyad Disciple gradient-capable thermal cycler (purchased separately). ... shuttle that contains four LEDs for fluorescence ... 620-650 nm) and two filtered photodiodes for ...
... (LCM) is the method of choice for ... the only instrument to offer both LCM ... UV Laser Cutting provides unprecedented ... and capturing large numbers of cells. , ...
... highly sensitive laser confocal systems designed for ... scanners that meet your expectations, differentiating between ... optimizing the signal on the bottom as ... range for increased sensitivity. Results with VersArray ...
Hybridizer (220 V) For more information, please visit Dako' web-site. EU regulatory status: CE US regulatory status: IVD...
Biology Products: